keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer therapy

keyword
https://www.readbyqxmd.com/read/30121715/management-of-brain-metastases-in-the-new-era-of-checkpoint-inhibition
#1
REVIEW
Adam Lauko, Bicky Thapa, Vyshak Alva Venur, Manmeet S Ahluwalia
PURPOSE OF THE REVIEW: Brain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases...
August 18, 2018: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/30121621/molecular-basis-of-distinct-oestrogen-responses-in-endometrial-and-breast-cancer
#2
Eva Baxter, Karolina Windloch, Greg Kelly, Jason S Lee, Frank Gannon, Donal Brennan
Up to 80% of endometrial and breast cancers express oestrogen receptor alpha (ERα). Unlike breast cancer, anti-oestrogen therapy has had limited success in endometrial cancer, raising the possibility that oestrogen has different effects in both cancers. We investigated the role of oestrogen in endometrial and breast cancers using data from The Cancer Genome Atlas (TCGA) in conjunction with cell line studies. Using phosphorylation of ERα (ERα-pSer118) as a marker of transcriptional activation of ERα in TCGA datasets, we found that genes associated with ERα-pSer118 were predominantly unique between tumour types and have distinct regulators...
August 18, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/30121489/a-pilot-study-of-a-body-image-intervention-for-breast-cancer-survivors
#3
Helena Lewis-Smith, Phillippa Claire Diedrichs, Diana Harcourt
Body image interventions for breast cancer survivors are lacking in empirical support. Examining existing research on effective body image interventions for women in midlife more broadly may provide useful insights. This pilot study assessed the acceptability, feasibility, and preliminary effects of a Cognitive Behavioural Therapy-based intervention adapted from women in midlife to promote positive body image among breast cancer survivors. Twenty-two breast cancer survivors received the 7-week group intervention, co-facilitated by a clinical psychologist and peer...
August 16, 2018: Body Image
https://www.readbyqxmd.com/read/30120166/prognostic-factors-in-patients-with-metastatic-breast-cancer-with-bone-only-metastases
#4
Amanda Parkes, Carla L Warneke, Katherine Clifton, Aydah Al-Awadhi, Oluchi Oke, Roberto Carmagnani Pestana, Omar Alhalabi, Jennifer K Litton, Gabriel N Hortobagyi
BACKGROUND: Patients with metastatic breast cancer with bone-only metastases (BOM) are a unique patient population without consensus regarding high-risk characteristics, which we sought to establish. METHODS: We identified 1,445 patients with BOM followed for at least 6 months at MD Anderson Cancer Center from January 1, 1997, to December 31, 2015. RESULTS: Seventy-one percent ( n = 936) of the 1,325 patients with BOM with available pain characterization were symptomatic at time of BOM diagnosis...
August 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30120164/clinicopathological-and-treatment-associated-prognostic-factors-in-patients-with-breast-cancer-leptomeningeal-metastases-in-relation-to-tumor-biology
#5
Gaia Griguolo, Stephane Pouderoux, Maria Vittoria Dieci, William Jacot, Céline Bourgier, Federica Miglietta, Nelly Firmin, Pierfranco Conte, Marie Viala, Valentina Guarneri, Amélie Darlix
BACKGROUND: Breast cancer (BC) is one of the solid tumors most commonly associated with leptomeningeal disease (LMD). LMD carries a devastating prognosis; however, disease presentation and prognostic factors are uncertain. SUBJECTS, MATERIALS, AND METHODS: In order to describe patient characteristics, treatment patterns, and factors associated with survival in a contemporary multicentric cohort, 153 consecutive BC patients diagnosed with LMD at two European institutions (2002-2017) were included...
August 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30120159/adjuvant-anthracyclines-in-breast-cancer-what-is-their-role
#6
REVIEW
Ami N Shah, William J Gradishar
Anthracyclines have been a mainstay of breast cancer therapy for decades, with strong evidence demonstrating their impact on breast cancer survival. However, concerns regarding rare but serious long-term toxicities including cardiotoxicity and hematologic malignancies have driven interest in alternative adjuvant therapy options with more favorable toxicity profiles. This article provides an update of data that help inform clinicians of the role anthracyclines should play in adjuvant breast cancer therapy. Two recently reported large randomized trials-the Anthracycline in Early Breast Cancer and Western German Study Plan B studies-compared a taxane and cyclophosphamide regimen with an anthracycline, taxane, and cyclophosphamide regimen...
August 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30120157/impact-of-guideline-discordant-treatment-on-cost-and-health-care-utilization-in-older-adults-with-early-stage-breast-cancer
#7
Courtney P Williams, Kelly M Kenzik, Andres Azuero, Grant R Williams, Maria Pisu, Karina I Halilova, Stacey A Ingram, Supriya K Yagnik, Andres Forero, Smita Bhatia, Gabrielle B Rocque
BACKGROUND: National Comprehensive Cancer Network (NCCN) guideline-based treatment is a marker of high-quality care. The impact of guideline discordance on cost and health care utilization is unclear. MATERIALS AND METHODS: This retrospective cohort study of Medicare claims data from 2012 to 2015 included women age ≥65 with stage I-III breast cancer receiving care within the University of Alabama at Birmingham Cancer Community Network. Concordance with NCCN guidelines was assessed for treatment regimens...
August 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30119663/a-multi-center-double-blind-randomized-controlled-trial-evaluating-flap-fixation-after-mastectomy-using-sutures-or-tissue-glue-versus-conventional-closure-protocol-for-the-seroma-reduction-after-mastectomy-sam-trial
#8
J van Bastelaar, R Granzier, L M van Roozendaal, G Beets, C D Dirksen, Y Vissers
BACKGROUND: Seroma formation is a common complication after mastectomy and is associated with delayed wound healing, infection, skin flap necrosis, patient discomfort and repeated visits to the out patient clinic to deal with seroma and its sequelae. Closing the dead space after mastectomy seems to be key in reducing seroma and its complications. Various methods have been described to reduce the dead space after mastectomy: closed suction drainage, quilting of the skin flaps and application of adhesive tissue glues...
August 17, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30119087/integrated-rehabilitation-for-breast-cancer-survivors
#9
Andrea L Cheville, Sarah A McLaughlin, Tufia Haddad, Kathleen D Lyons, Robin Newman, Kathryn J Ruddy
The physical and psychological side effects of breast cancer therapies can have substantial impact on survivors' physical and social functioning. Roughly half of the more than 3 million Americans alive with a history of breast cancer report adverse, function-degrading sequelae related to their oncologic treatments. Care delivery models for the timely delivery of rehabilitation services have been proposed yet limitedly vetted or implemented. These include the prospective surveillance model, procedure-linked referrals, survivorship care plans and risk stratification...
August 16, 2018: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/30118901/ribociclib-plus-letrozole-and-concomitant-palliative-radiotherapy-for-metastatic-breast-cancer
#10
Icro Meattini, Isacco Desideri, Vieri Scotti, Gabriele Simontacchi, Lorenzo Livi
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach. There are no available published data regarding the combination of ribociclib and palliative RT...
August 9, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30118822/fdg-pet-ct-based-lymph-node-atlas-in-breast-cancer-patients
#11
Kai Joachim Borm, Julia Voppichler, Mathias Düsberg, Markus Oechsner, Tibor Vag, Wolfgang Weber, Stephanie Elisabeth Combs, Marciana Nona Duma
PURPOSE: The aim of this study was to localize loco-regional lymph node metastases using positron emission tomography with fluorine 18 fluorodeoxyglucose/computed tomography (FDG-PET/CT) datasets in a large cohort of patients and to evaluate the existing Radiation Therapy Oncology Group (RTOG) clinical target volume (CTV) and the European SocieTy for Radiotherapy & Oncology (ESTRO) CTV contouring guidelines. METHODS: 235 patients with 580 FDG/PET-CT positive loco-regional lymph node metastases were included in our analysis...
August 14, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/30118453/feasibility-of-a-telemedicine-delivered-cognitive-behavioral-therapy-for-insomnia-in-rural-breast-cancer-survivors
#12
Michaela S McCarthy, Ellyn E Matthews, Catherine Battaglia, Paula M Meek
OBJECTIVES: To evaluate a nurse-led, telemedicine-delivered cognitive behavioral therapy for insomnia (CBTI) in rural breast cancer survivors (BCSs). SAMPLE & SETTING: 18 BCSs diagnosed with stage I-III breast cancer in the rural western United States. METHODS & VARIABLES: In this prospective, pre-/post-test, quasiexperimental feasibility pilot trial, BCSs attended six weekly sessions of CBTI via Internet videoconference. Feasibility was assessed using recruitment and acceptability of the intervention...
September 1, 2018: Oncology Nursing Forum
https://www.readbyqxmd.com/read/30118334/olaparib-tablets-for-the-treatment-of-germline-brca-mutated-metastatic-breast-cancer
#13
Dan Le, Karen A Gelmon
Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic HER2-negative breast cancer. Areas Covered Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has been shown in phase I-III clinical trials to have single-agent efficacy in breast cancer patients with gBRCAm. The recent phase III OlympiAD study demonstrated a statistically significant progression free survival benefit compared to the chemotherapy control arm, although an overall survival benefit has not been demonstrated...
August 17, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/30117777/a-preliminary-study-on-metadherin-as-a-potential-marker-for-progression-of-diffuse-large-b-cell-lymphoma
#14
Xueling Ge, Xiaohui Sui, Xiaosheng Fang, Yujie Jiang, Mei Ding, Xin Liu, Xin Wang
AIMS: To determine if Metadherin (MTDH) expression levels are positively correlated with the clinical stage of diffuse large B-cell lymphoma (DLBCL) based on MTDH being highly expressed in other type of tumors including melanoma, malignant glioma, breast cancer, and hepatocellular carcinoma. In this study, we investigated the pathologic significance of MTDH and its potential in predicting DLBCL outcomes. MATERIALS AND METHODS: Tissue samples from 50 patients with DLBCL and 22 patients with lymph node reactive hyperplasia were collected and evaluated using immunohistochemical staining, microscopy, and western blotting...
August 2018: Genetic Testing and Molecular Biomarkers
https://www.readbyqxmd.com/read/30117642/transcription-factor-atf3-mediates-the-radioresistance-of-breast-cancer
#15
Wenyan Zhao, Ming Sun, Shuqiang Li, Zhaofu Chen, Donghua Geng
This study was designed to research the influence of activating transcription factor 3 (ATF3) on the radioresistance of breast cancer. ATF3 expression was measured by qRT-PCR and immunohistochemistry. Cancerous cell lines were cultured in vitro, and the expression of ATF3 was gauged by both qRT-PCR and Western blot before and after the radiation therapy. Cellular cycle and apoptosis were analysed by flow cytometry. Changes in the expression of corresponding proteins in the downstream pathways were identified by Western blot...
August 17, 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/30117343/clinical-benefits-of-acupuncture-for-the-reduction-of-hormone-therapy-related-side-effects-in-breast-cancer-patients-a-systematic-review
#16
Yuanqing Pan, Kehu Yang, Xiue Shi, Haiqian Liang, Xiping Shen, Renjie Wang, Li Ma, Qi Cui, Runze Yu, Yi Dong
IMPORTANCE: Acupuncture can help reduce unpleasant side effects associated with endocrine therapy for breast cancer. Nevertheless, comprehensive evaluation of current evidence from randomized controlled trials(RCTs) is lacking. OBJECTIVE: To estimate the efficacy of acupuncture for the reduction of hormone therapy-related side effects in breast cancer patients. EVIDENCE REVIEW: RCTs of acupuncture in breast cancer patients that examined reductions in hormone therapy-related side effects were retrieved from PubMed, EMBASE, Web of Science, Ovid MEDLINE, and Cochrane Library databases through April 2016...
September 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/30117065/fluidic-shear-stress-increases-the-anti-cancer-effects-of-ros-generating-drugs-in-circulating-tumor-cells
#17
Sagar Regmi, To Sing Fung, Sierin Lim, Kathy Qian Luo
PURPOSE: Many anti-cancer drugs are used in chemotherapy; however, little is known about their efficacy against circulating tumor cells (CTCs). In this study, we investigated whether the pulsatile fluidic shear stress (SS) in human arteries can affect the efficacy of anti-cancer drugs. METHODS: Cancer cells were circulated in our microfluidic circulatory system, and their responses to drug and SS treatments were determined using various assays. Breast and cervical cancer cells that stably expressed apoptotic sensor proteins were used to determine apoptosis in real-time by fluorescence resonance energy transfer (FRET)-based imaging microscopy...
August 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30116683/an-attempt-to-quantitate-value-in-medical-oncologic-therapy
#18
Christie Hancock, Linda Green, Timothy Lestingi, Jacob Bitran Md
Objective We wanted to examine the incremental cost-effective ratio (ICER) for a variety of Food and Drug Administration (FDA) approved oncology drugs in the adjuvant or curative setting to determine the value provided. Design We examined the annualized incremental drug costs of a variety of FDA approved chemotherapeutic drugs used in an adjuvant or curative setting based on National Comprehensive Cancer Network (NCCN) category 1 practice guidelines for melanoma, Her2/neu over-expressive breast cancer, renal cell carcinoma, stage IIIA non-small cell lung cancer, myeloma, B cell lymphoma, and Hodgkin lymphoma...
June 14, 2018: Curēus
https://www.readbyqxmd.com/read/30116283/advances-in-the-use-of-parp-inhibitor-therapy-for-breast-cancer
#19
REVIEW
Kelly E McCann, Sara A Hurvitz
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described. BRCA1 and BRCA2 (Breast Cancer) proteins are involved in homologous recombination repair (HRR), which requires a homologous chromosome or sister chromatid as a template to faithfully repair DNA double-strand breaks. The small-molecule NAD+ mimetics, olaparib, niraparib, rucaparib, veliparib, and talazoparib, inhibit the catalytic activity of PARP-1 and PARP-2 and are currently being studied in later-stage clinical trials...
2018: Drugs in Context
https://www.readbyqxmd.com/read/30116102/a-novel-approach-for-identifying-relevant-genes-for-breast-cancer-survivability-on-specific-therapies
#20
REVIEW
Ashraf Abou Tabl, Abedalrhman Alkhateeb, Huy Quang Pham, Luis Rueda, Waguih ElMaraghy, Alioune Ngom
Analyzing the genetic activity of breast cancer survival for a specific type of therapy provides a better understanding of the body response to the treatment and helps select the best course of action and while leading to the design of drugs based on gene activity. In this work, we use supervised and nonsupervised machine learning methods to deal with a multiclass classification problem in which we label the samples based on the combination of the 5-year survivability and treatment; we focus on hormone therapy, radiotherapy, and surgery...
2018: Evolutionary Bioinformatics Online
keyword
keyword
168559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"